CNS 将在2025年11月的神经肿瘤会议上介绍CNSPharma的Glioblastoma药物数据。 CNS Pharma's glioblastoma drug data to be presented at Nov. 2025 neuro-oncology conference.

CNS制药公司已宣布,其三份研究摘要已被接受在定于2025年11月举行的神经肿瘤学会第三十届年会上作海报展示。 CNS Pharmaceuticals has announced that three of its research abstracts have been accepted for poster presentation at the Society for Neuro-Oncology’s 30th Annual Meeting, scheduled for November 2025. 所接受的研究侧重于血浆瘤治疗的进展,包括公司调查药物、基于蒸气的 Temozolomide 及其改善脑肿瘤患者结果的潜力的数据。 The accepted studies focus on advancements in glioblastoma treatment, including data on the company’s investigational drug, pamoate-based temozolomide, and its potential to improve outcomes for patients with aggressive brain tumors. 这些介绍将介绍临床和临床前期调查结果的最新情况,为正在进行的神经肿瘤研究作出贡献。 The presentations will provide updates on clinical and preclinical findings, contributing to ongoing research in neuro-oncology.